ALNYLAM PHARMA (DUL MU) stock market data APIs
€399.777
0.44(0.1%)
as of October 24, 2025
Try our APIs with
free plan!
ALNYLAM PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for DUL.MU.
Prev. Close
399.777
Open
400.2154
High
399.777
Low
400.2154
52 wk Range
192.15-419
Market Cap
18 390 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALNYLAM PHARMA data using free add-ons & libraries
Get ALNYLAM PHARMA Fundamental Data
ALNYLAM PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 1.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALNYLAM PHARMA News
New
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
The market expects Alnylam Pharmaceuticals (ALNY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known co...
Why Alnylam (ALNY) Might be Well Poised for a Surge
Investors might want to bet on Alnylam Pharmaceuticals (ALNY), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price mo...
Alnylam price target raised to $535 from $459 at Truist
Truist raised the firm’s price target on Alnylam (ALNY) to $535 from $459 and keeps a Buy rating on the shares ahead of its Q3 results. The firm has increased its Q3 Amvuttra sales estimate to $690M...
S&P 500's Walmart In Buy Zone, Leads Five Stocks Near Buy Points
S&P 500 giant Walmart and a profitable biotech are actionable, leading five stocks to watch amid a tricky market environment. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
